Matinas BioPharma Holdings MTNB
NYSE MTNB
$0.19 -0.05 (-20.83%)
At close: Aug 20, 2026 · 4:00 PM EDT

Matinas BioPharma Holdings (MTNB) Current Deferred Revenue (2015 - 2022)

Matinas BioPharma Holdings (MTNB) posted quarterly Current Deferred Revenue of $721000.0 for Q4 2022, up 2308.39% quarter-over-quarter from $29937.0 in Q4 2017.

Matinas BioPharma Holdings (MTNB) Current Deferred Revenue (2015 - 2022) Analysis & Trends

Matinas BioPharma Holdings (MTNB) has reported Current Deferred Revenue for 4 consecutive years, with $721000.0 the latest figure, recorded in Q4 2022.

  • In Q4 2022, Current Deferred Revenue changed N/A year-over-year to $721000.0; the TTM figure through Dec 2022 stood at $721000.0 (changed N/A YoY), while the FY2022 annual figure was $721000.0, changed N/A from the prior year.
  • Current Deferred Revenue advanced to $721000.0 in Q4 2022 per MTNB's latest filing, from $29937.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $721000.0 in Q4 2022 and bottomed at $721000.0 in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 137.11 Bn 129.26 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 84.98 Bn 76.99 Bn 3.93 Bn
3 Argenx Se 64.52 Bn 59.33 Bn 1.37 Bn
4 Moderna 53.23 Bn 48.09 Bn 52.00 Mn
5 BeOne Medicines 41.23 Bn 36.14 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 30.65 Bn 27.34 Bn 992.69 Mn
7 Insmed 27.15 Bn 25.99 Bn 358.27 Mn
8 Royalty Pharma 26.98 Bn 26.14 Bn -
9 BioNTech SE 26.78 Bn 8.39 Bn 668.28 Mn
10 Matinas BioPharma Holdings 1.19 Mn 375,426.61 -

Historic Data

Download Data
DateValue
Dec 31, 2022 721,000.00
Dec 31, 2017 29,937.00
Sep 30, 2017 74,844.00
Jun 30, 2017 119,750.00
Mar 31, 2017 11,744.00
Dec 31, 2016 11,485.00
Sep 30, 2016 11,226.00
Jun 30, 2016 10,967.00
Mar 31, 2016 10,218.00
Dec 31, 2015 9,225.00
Sep 30, 2015 8,232.00
Jun 30, 2015 7,239.00
Mar 31, 2015 5,757.00